Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
Just as demand for coronavirus tests is peaking, the US regulator has a quiet week.
At least two groups have posted early data on T-cell tests for Covid-19; now Qiagen has licensed tech to make its own.
Oxford Immunotec’s test might be able to pinpoint those at low risk of reinfection.
Despite the FDA’s warning that antigen assays may only be used in patients with symptoms, one such test shows potential in the screening setting.
Omada is better funded than its digital health rival Livongo, but can it achieve a similar valuation?